Apellis

formerly Apellis PharmaceuticalsIPO

Courageous Science + Compassion

Public · Waltham, United States · Founded 2009 · $522.6M raised

Employees
501–1000
Founded
2009
Business Model
B2B
Total Funding
$522.6M
Last Round
$32.5M Series AFeb 2023
Rounds
5
Type
Public

About

Apellis Pharmaceuticals (Nasdaq: APLS) is a clinical-stage and commercial-stage biopharmaceutical company focused on the complement system, a key branch of innate immunity. Founded in 2009 by Cedric Francois and Dinesh Bhatt, the company pioneered targeted C3 inhibition with its lead compound pegcetacoplan. Apellis received FDA approval for EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH) in 2021 and SYFOVRE for geographic atrophy (GA) in 2023 — the first approved treatment for GA. Headquartered in Waltham, Massachusetts.

Summary

Apellis is a Biotech company based in Waltham, United States, founded in 2009. It has raised $522.6M in total across 5 rounds, most recently a $32.5M Series A round in Feb 2023. Investors include Unknown Ventures, Biogen and AJU IB Investment.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionJun 2026
$5.6B

Sign up to see all 10 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Apellis on Indexed.vc
<a href="https://indexed.vc/companies/apellis"><img src="https://indexed.vc/api/badge/company/apellis" alt="Apellis on Indexed.vc" width="260" height="76" /></a>